Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...

SARS-CoV-2, the virus responsible for COVID-19, infects cells by binding its spike protein to angiotensin-converting enzyme 2 ...

Kei Sato was looking for his next big challenge five years ago when it smacked him — and the world — in the face. The ...

COVID infections, even if mild or asymptomatic, may be causing long-term cellular and organ damage, as well as increasing ...

Monoclonal antibodies like etesevimab have lost efficacy against Omicron subvariants, necessitating innovative solutions.

When the COVID-19 pandemic first began, we saw how quickly the SARS-CoV-2 virus evolved. New variants emerged with mutations that increased transmissibility or helped the virus evade our immune ...

Shaibani, A. , Maallah, M. and Maallah, A. (2025) Antiviral Activity of Natural Compounds Immuno Formula Shiban2/5 against ...

One avenue for new vaccine development is mucosal vaccines. In theory, dosing the vaccine directly into the respiratory tract ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

Data provided to U.S. FDA, with update to PEMGARDA Fact Sheet for Healthcare ... 1, KP.3.1.1, XEC, and LP.8.1. PEMGARDA targets the SARS-CoV-2 spike protein receptor binding domain (RBD), thereby ...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...